Table of contents

Preliminary material: Acknowledgments; Abbreviations; Symbols

A summary of alcohol and other drug treatment in 2009–10

1 Introduction

  • Definitions of terms used in this report
  • 1.1 How are the data collected?
  • 1.2 What's included?
    • 1.2.1 Agencies and clients included
    • 1.2.2 Agencies and clients excluded
  • 1.3 Important issues that explain the data
    • 1.3.1 Clients are not counted
    • 1.3.2 Funding source cannot be differentiated
    • 1.3.3 Covering of Indigenous substance use services is limited
    • 1.3.4 Implementation makes a difference
  • 1.4 Data issues specific to the 2009–10 year
  • 1.5 Explanatory notes

2 Treatment agencies–what sector and where are the treatment agencies?

  • 2.1 Service sector
  • 2.2 Locations
  • 2.3 Treatment types reporting from different geographical locations

3 Clients – who uses alcohol and other drug treatment services?

  • 3.1 Own or other's drug use
    • 3.1.1 Across Australia
    • 3.1.2 Age and sex
  • 3.2 Indigenous Australians
    • 3.2.1 Indigenous clients in the AODTS-NMDS collection
    • 3.2.2 Care provided by OATSIH-funded substance use-specific services
  • 3.3 Country of birth and preferred language

4 Drugs of concern–what drugs do people seek treatment for?

  • 4.1 Principal drugs of concern
    • 4.1.1 Principal drugs of concern across Australia
    • 4.1.2 Principal drugs of concern over time
    • 4.1.3 Age and principal drug of concern
    • 4.1.4 Sex and principal drugs of concern
    • 4.1.5 Indigenous Australians and principal drug of concern
  • 4.2 Individual principal drug of concern profiles
    • 4.2.1 Alcohol
      • Patterns of use in Australia
      • Drug profile
      • Client profile
      • Treatment profile
    • 4.2.2 Cannabis
      • Patterns of use in Australia
      • Drug profile
      • Client profile
      • Treatment profile
    • 4.2.3 Heroin
      • Patterns of use in Australia
      • Drug profile
      • Client profile
      • Treatment profile
    • 4.2.4 Amphetamines
      • Patterns of use in Australia
      • Drug profile
      • Client profile
      • Treatment profile
    • 4.2.5 Benzodiazepines
      • Patterns of use in Australia
      • Drug profile
      • Client profile
      • Treatment profile
    • 4.2.6 Ecstasy
      • Patterns of use in Australia
      • Drug profile
      • Client profile
      • Treatment profile
    • 4.2.7 Cocaine
      • Patterns of use in Australia
      • Drug profile
      • Client profile
      • Treatment profile
  • 4.3 All drugs of concern

5 Treatment – what treatments do people receive?

  • 5.1 Main treatment
    • 5.1.1 Main treatment types across Australia
    • 5.1.2 Main treatment types over time
    • 5.1.3 Aboriginal and Torres Strait Islander people and treatment programs
    • 5.1.4 Reasons for leaving treatment
  • 5.2 Specific main treatment types
    • 5.2.1 Counselling
      • Principal drug profile
      • Client profile
      • Treatment profile
    • 5.2.2 Withdrawal management (detoxification)
      • Principal drug profile
      • Client profile
      • Treatment profile
    • 5.2.3 Assessment only
      • Principal drug profile
      • Client profile
      • Treatment profile
    • 5.2.4 Information and education only
      • Principal drug profile
      • Client profile
      • Treatment profile
    • 5.2.5 Support and case management only
      • Principal drug profile
      • Client profile
      • Treatment profile
    • 5.2.6 Rehabilitation
      • Principal drug profile
      • Client profile
      • Treatment profile
    • 5.2.7 Other main treatment types
      • Principal drug profile
      • Client profile
      • Treatment profile
  • 5.3 Additional treatments
  • 5.4 National Opioid Pharmacotherapy Statistics Annual Data Collection 2010
    • 5.4.1 Number of clients receiving pharmacotherapy treatment
  • 5.5 Opioid pharmacotherapy treatment in prison health services 2010

6 Hospital treatment – what drug-related diagnoses do people go to hospital for?

  • 6.1 Drug-related hospital separations in 2009–10
    • 6.1.1 Drugs associated with hospital separations
    • 6.1.2 Hospital separations by sex
    • 6.1.3
    • 6.1.3 Hospital separations by age
    • 6.1.4 Hospital separations by socioeconomic status
    • 6.1.5 Hospital separations among Indigenous Australians
    • 6.1.6 Public versus private hospitals
  • 6.2 Hospital separation trends

7 Collection methods and data quality – how are the data collected?

  • 7.1 Collection method and data included
  • 7.2 Comprehensiveness of the data
    • 7.2.1 Australian Government data
    • 7.2.2 Data quality
  • 7.3 Policy and administrative features in each jurisdiction
  • 7.4 Data quality considerations for other collections

Appendix 1: About the collection

  • Responsibility for the collection
  • Government health authorities
  • Alcohol and other drug treatment agencies
  • AIHW
  • Using AODTS–NMDS Data

Appendix 2: Data elements in the AODTS NMDS for 2009–10

Appendix 3: Detailed tables

  • Agency tables
  • Client profile tables
  • Drugs of concern tables
  • Treatment program tables
  • Hospital separation tables

Appendix 4: Australian Standard Geographical Classification

Appendix 5: Australian Standard Classification of Drugs of Concern (ASCDC)

  • 1 Analgesics
    • 11 Organic Opiate Analgesics
    • 12 Semisynthetic Opioid Analgesics
    • 13 Synthetic Opioid Analgesics
    • 14 Non Opioid Analgesics
  • 2 Sedatives and hypnotics
    • 21 Alcohols
    • 22 Anaesthetics
    • 23 Barbiturates
    • 24 Benzodiazepines
    • 29 Other Sedatives and Hypnotics
  • 3 Stimulants and hallucinogens
    • 31 Amphetamines
    • 32 Cannabinoids
    • 33 Ephedra Alkaloids
    • 34 Phenethylamines
    • 35 Tryptamines
    • 36 Volatile Nitrates
    • 39 Other Stimulants and Hallucinogens
  • 4 Anabolic agents and selected hormones
    • 41 Anabolic Androgenic Steroids
    • 42 Beta Agonists
    • 43 Peptide Hormones, Mimetics and Analogues
    • 49 Other Anabolic Agents and Selected Hormones
  • 5 Antidepressants and antipsychotics
    • 51 Monoamine Oxidase Inhibitors
    • 52 Phenothiazines
    • 53 Serotonin Reuptake Inhibitors
    • 54 Thioxanthenes
    • 55 Tricyclic Antidepressants
    • 59 Other Antidepressants and Antipsychotics
  • 6 Volatile solvents
    • 61 Aliphatic Hydrocarbons
    • 62 Aromatic Hydrocarbons
    • 63 Halogenated Hydrocarbons
    • 69 Other Volatile Solvents
  • 9 Miscellaneous drugs of concern
    • 91 Diuretics
    • 92 Opioid Antagonists
    • 99 Other Drugs of Concern

Appendix 6: Alcohol and other drug treatment provided by services funded to assist Aboriginal and Torres Strait Islander people

  • Substance use-specific services
  • Substance use treatment and assistance
    • Substances as a specifically targeted program
    • Substances on an individual client basis

Appendix 7: Mapping of ICD-10-AM codes to ASCDC output categories

End matter: References; List of tables; List of figures; List of boxes